45.00
-0.18(-0.40%)
Currency In USD
| Previous Close | 45.18 |
| Open | 45.25 |
| Day High | 45.8 |
| Day Low | 44.92 |
| 52-Week High | 50.79 |
| 52-Week Low | 23.23 |
| Volume | 209,407 |
| Average Volume | 479,128 |
| Market Cap | 1.42B |
| PE | 27.61 |
| EPS | 1.63 |
| Moving Average 50 Days | 47.27 |
| Moving Average 200 Days | 37.62 |
| Change | -0.18 |
If you invested $1000 in Collegium Pharmaceutical, Inc. (COLL) 10 years ago, it would be worth $2,154.14 as of February 21, 2026 at a share price of $45. Whereas If you bought $1000 worth of Collegium Pharmaceutical, Inc. (COLL) shares 5 years ago, it would be worth $1,822.6 as of February 21, 2026 at a share price of $45.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026
GlobeNewswire Inc.
Feb 12, 2026 1:00 PM GMT
STOUGHTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2025 financial results before the market opens on Thursday, February 26, 2026. Follow
Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference
GlobeNewswire Inc.
Jan 15, 2026 1:00 PM GMT
STOUGHTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have four poster presentations highlighting real-world data from its ADHD product, Jornay PM (methylphenidate HCl), a central
Collegium Provides 2026 Financial Guidance and Business Update
GlobeNewswire Inc.
Jan 08, 2026 1:00 PM GMT
– Product Revenues, Net Expected in the Range of $805 Million to $825 Million – – Jornay PM® Net Revenue Expected in the Range of $190 Million to $200 Million – – Adjusted EBITDA* Expected in the Range of $455 Million to $475 Million – STOUGHTON, Mas